Company intelligence / Profile preview

Wren Capital

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Wren Therapeutics has raised approximately £33 million to advance a chemical kinetics-based drug discovery platform for protein misfolding diseases. Lead programs target amyloid-beta and alpha-synuclein, advancing towards clinic. Collaboration with Eisai underway for small molecule discovery in synucleinopathies. No clinical data reported yet.

Therapeutic areas: NeurologyEndocrinologyRare Diseases
Modalities: Small moleculeAntibody
Industry: Biotech

Partnerships

Eisai

Beyond the preview

Go deeper on Wren Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wren Capital.

Explore the full profile